Glenmark Receives US FDA Approval for Progesterone Inserts

Glenmark Pharmaceuticals received final US FDA approval for its Progesterone Vaginal Inserts, 100 mg, deemed bioequivalent to Ferring's Endometrin®.
The approved product addresses a US market with annual sales of approximately $59.2 million based on IQVIA data through February 2026.
Glenmark Pharmaceuticals Inc., USA will distribute the product, strengthening the company's focus on women's healthcare portfolio.
This regulatory filing serves as an official disclosure to stock exchanges regarding the new product approval.